UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of September 2022

 

Commission File Number: 001-41440

 

Virax Biolabs Group Limited

(Registrant’s Name)

 

30 Broadwick Street

London, W1F 8LX

United Kingdom

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

 

 


When used in this Current Report on Form 8-K, unless otherwise indicated, the terms “the Company,” “Virax,” “we,” “us” and “our” refer to Virax Biolabs Group Limited. and its subsidiaries.

 

Item 7.01 Regulation FD Disclosure.

 

On September 6, 2022, Virax Biolabs Group Limited issued a press release announcing that the Company will be presenting at the H.C. Wainwright Annual Global Investment Conference from September 12 - 14, 2022 at the Lotte New York Palace Hotel, New York, NY.

 

A copy of the press release dated September 6, 2022 is included as Exhibit 99.1 to this report.

 

Item 9.01 Financial Statements and Exhibits.

 

 

 

 

(d)

Exhibits

 

 

 

 

Exhibit No

 

Description

 

 

 

99.1

 

Press Release dated September 6, 2022

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

 

 

VIRAX BIOLABS GROUP LIMITED

 

 

 

 

Date:

September 7, 2022

By:

/s/ Jason Davis

 

 

 

Jason Davis, Chief Financial Officer